A(3) Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural Mesothelioma

Human malignant pleural mesothelioma (MPM) is a rare, but aggressive tumor of the serosal cavities whose 5-year survival rate is 15%. At present, there are no effective therapies for MPM. Although recent findings suggest that A(3) adenosine (A(3)AR) and P2X7 (P2X7R) receptors can be employed as anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincenzi, Fabrizio, Rotondo, John Charles, Pasquini, Silvia, Di Virgilio, Francesco, Varani, Katia, Tognon, Mauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518529/
https://www.ncbi.nlm.nih.gov/pubmed/34660262
http://dx.doi.org/10.3389/fonc.2021.679285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518529/
https://www.ncbi.nlm.nih.gov/pubmed/34660262
http://dx.doi.org/10.3389/fonc.2021.679285

Ejemplares similares